scholarly journals Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study

2015 ◽  
Vol 3 (2) ◽  
pp. 45-55 ◽  
Author(s):  
Mariusz Stasiolek ◽  
Ralf A. Linker ◽  
Liat Hayardeny ◽  
Oren Bar Ilan ◽  
Ralf Gold
Keyword(s):  
Multiple Sclerosis ◽  
Oral Therapy ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Immune Parameters

Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised, placebo-controlled, double blind trial in Norway

1996 ◽  
Vol 1 (6) ◽  
pp. 372-375 ◽  
Author(s):  
H Nyland ◽  
K-M Myhr ◽  
F Lillås ◽  
AI Smievoll ◽  
T Riise ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Primary Objective ◽  
Interferon Alfa ◽  
Controlled Study ◽  
Human Interferon ◽  
New Disease ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Drug Free

A multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy and safety of 4.5 and 9.0 MIU recombinant human interferon alfa-2a (Rof eron-A™) given thrice weekly in patients with relapsing-remittent multiple sclerosis is described. The patients are treated for 6 months followed by a 6 months drug-free period. The primary objective is to determine new disease activity analysed by monthly MRI with gadodiamide (GdDTPA-BMA, Omniscan™). The study is conducted at eight centers in Norway and is completed in January 1996.

Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebo-controlled study

1996 ◽  
Vol 2 (5) ◽  
pp. 227-232 ◽  
Author(s):  
Jorgen F Nielsen ◽  
Thomas Sinkjaer ◽  
Johannes Jakobsen
Keyword(s):  
Multiple Sclerosis ◽  
Stretch Reflex ◽  
Magnetic Stimulation ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Future Studies ◽  
Sham Stimulation ◽  
Repetitive Magnetic Stimulation ◽  
Reflex Threshold

The effect of repetitive magnetic stimulation on spasticity was evaluated in 38 patients with multiple sclerosis in a double-blind placebo-controlled study. One group was treated with repetitive magnetic stimulation (n=2l) and the other group with sham stimulation (n=l7). Both groups were seated twice daily for 7 consecutive days. Primary end-points of the study were changes in the patients self-score, in clinical spasticity score, and in the stretch reflex threshold. The self-score of ease of daily day activities improved by 22% (P=0.007) after treatment and by 29% (P=0.004) after sham stimulation. The clinical spasticity score improved 3.3±4.7 arbitrary unit (AU) in treated patients and 0.7±2.5 AU in sham stimulation (P-0.003). The stretch reflex threshold increased 4.3±7.5 degls in treated patients and-3.8±9.7 degls in sham stimulation (P=0.001). The data presented in this study supports the idea that repetitive magnetic stimulation has an antispastic effect in multiple sclerosis. Future studies should darify the optimal treatment regimen.

scholarly journals MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study

CNS Drugs ◽  
2018 ◽  
Vol 32 (7) ◽  
pp. 661-672 ◽  
Author(s):  
Ayman Tourbah ◽  
Olivier Gout ◽  
Alain Vighetto ◽  
Véronique Deburghgraeve ◽  
Jean Pelletier ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Optic Neuritis ◽  
Visual Loss ◽  
Controlled Study ◽  
High Dose ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study

2011 ◽  
Vol 107 (6) ◽  
pp. 876-884 ◽  
Author(s):  
Giuliano Rizzardini ◽  
Dorte Eskesen ◽  
Philip C. Calder ◽  
Amedeo Capetti ◽  
Lillian Jespersen ◽  
...  
Keyword(s):  
Influenza Vaccination ◽  
Effective Means ◽  
Innate Immune ◽  
Lactobacillus Paracasei ◽  
Secretory Iga ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Bifidobacterium Animalis ◽  
Immune Parameters

The present study investigated the ability of Bifidobacterium animalis ssp. lactis (BB-12®) and Lactobacillus paracasei ssp. paracasei (L. casei 431®) to modulate the immune system using a vaccination model in healthy subjects. A randomised, double-blind, placebo-controlled, parallel-group study was conducted in 211 subjects (56 % females, mean age 33·2 (sd 13·1) years). Subjects consumed a minimum of 109 colony-forming units of BB-12® (capsule) or L. casei 431® (dairy drink) or a matching placebo once daily for 6 weeks. After 2 weeks, a seasonal influenza vaccination was given. Plasma and saliva samples were collected at baseline and after 6 weeks for the analysis of antibodies, cytokines and innate immune parameters. Changes from baseline in vaccine-specific plasma IgG, IgG1 and IgG3 were significantly greater in both probiotic groups v. the corresponding placebo group (L. casei 431®, P = 0·01 for IgG; P < 0·001 for remaining comparisons). The number of subjects obtaining a substantial increase in specific IgG (defined as ≥ 2-fold above baseline) was significantly greater in both probiotic groups v. placebo (BB-12®, P < 0·001 for IgG, IgG1 and IgG3; L. casei 431®, P < 0·001 for IgG1 and IgG3). Significantly greater mean fold increases for vaccine-specific secretory IgA in saliva were observed in both probiotic groups v. placebo (BB-12®, P = 0·017; L. casei 431®, P = 0·035). Similar results were observed for total antibody concentrations. No differences were found for plasma cytokines or innate immune parameters. Data herein show that supplementation with BB-12® or L. casei 431® may be an effective means to improve immune function by augmenting systemic and mucosal immune responses to challenge.

Sign in / Sign up

Export Citation Format

Share Document